1097-0231/asset/RCM_left.gif?v=1&s=91be5e0205fbe00fe36141e410291b5802ce099f)
Research Article
Lipidomic analysis of twenty-seven prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry
Article first published online: 20 SEP 2006
DOI: 10.1002/rcm.2697
Copyright © 2006 John Wiley & Sons, Ltd.
Issue
1097-0231/asset/cover.gif?v=1&s=685086e2b20ab07e9ab5ac022b9782ebdcd7ce5c "Rapid Communications in Mass Spectrometry")
Rapid Communications in Mass Spectrometry
Volume 20, Issue 20, pages 3023–3029, 30 October 2006
Additional Information
How to Cite
Masoodi, M. and Nicolaou, A. (2006), Lipidomic analysis of twenty-seven prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom., 20: 3023–3029. doi: 10.1002/rcm.2697
Publication History
- Issue published online: 20 SEP 2006
- Article first published online: 20 SEP 2006
- Manuscript Accepted: 5 AUG 2006
- Manuscript Revised: 31 JUL 2006
- Manuscript Received: 22 MAY 2006
Funded by
- The Wellcome Trust. Grant Number: 077850/Z/05/Z
Abstract
Prostanoids are potent mediators of many physiological and pathophysiological processes. Of the many analytical methodologies used for their qualitative and quantitative analysis, electrospray tandem mass spectrometry coupled to liquid chromatography (LC/ESI-MS/MS) offers a rapid, sensitive and versatile system applicable to lipidomic analyses. We have developed an LC/ESI-MS/MS assay for twenty-seven mediators including prostaglandins, prostacyclines, thromboxanes, dihydroprostaglandins and isoprostanes. The assay was liner over the concentration range 1–100 pg/µL. The limits of detection and quantitation were 0.5–50 and 2–100 pg, respectively, whilst recoveries were from 83–116% depending on the metabolite. The assay can be applied to the profiling of prostanoids produced by a variety of biological fluids and extracts including brain, liver, plasma and urine, thus facilitating our understanding of the role of these lipid mediators in health and disease, as well as assisting in drug development. Copyright © 2006 John Wiley & Sons, Ltd.